Earlier Briumvi use linked to less MS worsening at 5 years
Key Takeaway
Adults with relapsing MS who started Briumvi earlier had fewer flare-ups and less disability worsening after five years.
What They Found
The study followed adults who continued ublituximab (Briumvi) or switched from teriflunomide (Aubagio) to Briumvi. In the year after switching, the group's average flare-up rate fell by about 58%. Flare-up rates kept falling in both groups through year five. By year five, disability had worsened in about 8% of those who started Briumvi earlier, compared with about 14% who switched later. Serious infection rates were similar between the groups.
Who Should Care and Why
The researchers studied adults with relapsing MS who completed two earlier treatment trials. Some had taken Briumvi from the start, while others began with Aubagio. This comparison helps show what happened when people switched to Briumvi after the earlier trials. Those who started Briumvi earlier were less likely to have worsening disability by year five. The findings also describe flare-ups and serious infections during longer-term Briumvi use.
Important Considerations
You should know that 851 adults entered this follow-up study after completing earlier randomized trials. In the follow-up, everyone received Briumvi, so it did not compare the two drugs throughout all five years. The abstract does not show whether the same results would apply to people with other forms of MS.
AI-generated summary — for informational purposes only, not medical advice
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
10/9/2026
A mouse study suggests prepared red blood cells may calm MS-like immune attacks. Learn why liver cel
Read More
10/7/2026
A 3D-printed immune implant eased advanced MS-like disease in mice without broadly weakening immunit
Read More
10/6/2026
Researchers found immune cells that swap surface tags in MS. An MS treatment removed them in the stu
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.